Edition:
United States

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

65.57USD
26 May 2017
Change (% chg)

$-0.45 (-0.68%)
Prev Close
$66.02
Open
$66.07
Day's High
$66.59
Day's Low
$65.27
Volume
192,499
Avg. Vol
272,175
52-wk High
$75.13
52-wk Low
$35.94

Latest Key Developments (Source: Significant Developments)

Immunomedics announces private placement offering
Friday, 5 May 2017 08:46am EDT 

May 5 (Reuters) - Immunomedics Inc : :Immunomedics delivers business updates, announces private placement offering and outlines strategic steps to drive stockholder value.Immunomedics Inc - cfo michael garone to be named interim ceo once settlement agreement is finalized.Immunomedics Inc - board in process of considering candidates for permanent CEO.Immunomedics - has raised $125 million in gross proceeds in private placement of its series A-1 convertible preferred stock with institutional investors.Immunomedics Inc - now targeting submission of a BLA for Immu-132 for approval in MTNBC between late Q4 2017 and q1 2018.Immunomedics - to proceed with final selection of cro to launch confirmatory phase 3 study, expect first patient enrolled in late Q3 2017 for immu-132.Immunomedics Inc - Cynthia L. Sullivan will be stepping down from all director and officer positions with company.Immunomedics Inc - David M. Goldenberg, founder of company, is stepping down from all officer positions with company.Immunomedics Inc - Goldenberg will continue to serve as a director on Immunomedics' board.Immunomedics Inc - entered into a binding term sheet with Goldenberg, Sullivan, Markison and Venbio.Immunomedics Inc - Immunomedics expects to have sufficient operating funds through Q3 of 2018.Immunomedics Inc - regarding venbio action, individual defendants Goldenberg, Sullivan And Markison will be released from all claims made by Venbio.  Full Article

Seattle Genetics terminates license agreement with Immunomedics
Friday, 5 May 2017 08:00am EDT 

May 5 (Reuters) - Seattle Genetics Inc ::Seattle Genetics terminates license agreement with Immunomedics for sacituzumab govitecan (immu-132).As part of termination, Seattle Genetics will continue to hold 3.0 million shares of Immunomedics common stock.Seattle Genetics-effective upon termination of license, parties agreed to fully settle, resolve, release each other from all disputes, claims, liabilities.  Full Article

Seattle Genetics Q1 loss per share $0.42
Thursday, 27 Apr 2017 04:02pm EDT 

April 27 (Reuters) - Seattle Genetics Inc :Seattle genetics reports first quarter 2017 financial results.Q1 loss per share $0.42.Q1 revenue $109.1 million versus $111.2 million.Q1 earnings per share view $-0.42, revenue view $102.9 million -- Thomson Reuters I/B/E/S.  Full Article

Seattle Genetics says court issued temporary restraining order enjoining taking action in furtherance of closing of license agreement with Immunomedics
Friday, 10 Mar 2017 07:44am EST 

Seattle Genetics Inc : Seattle Genetics- On March 9,court issued temporary restraining order enjoining taking action in furtherance of closing of license agreement with Immunomedics . Seattle Genetics-Temporary restraining order to remain in place pending hearing on application for preliminary injunction to be held in about 30 days .Seattle Genetics - Restraining order regarding license agreement between co and Immunomedics, Inc. regarding Sacituzumab Govitecan.  Full Article

FDA lifts hold on Seattle Genetics' phase 1 trials of vadastuximab talirine
Monday, 6 Mar 2017 06:45am EST 

Seattle Genetics Inc : FDA lifts clinical hold on seattle genetics' phase 1 trials of vadastuximab talirine . Seattle genetics inc - seattle genetics will resume two phase 1 trials of vadastuximab talirine . Seattle genetics inc - will not resume phase 1/2 trial of vadastuximab talirine monotherapy in pre- and post-allogeneic transplant aml patients . Seattle genetics inc - continuing to enroll our ongoing phase 3 randomized cascade trial in frontline older aml patients . Seattle genetics inc - we are continuing to enroll our phase 1/2 trial in frontline high-risk myelodysplastic syndrome . Seattle genetics-planned studies include phase 2 trial of vadastuximab talirine in combination with 7+3 chemotherapy in frontline younger aml patients . Seattle genetics-additional risk mitigation measures will be implemented in all vadastuximab talirine studies .Seattle genetics - will resume two phase 1 trials in aml and plan to initiate a randomized phase 2 trial during 2017 evaluating vadastuximab talirine.  Full Article

Immunomedics says to seek expedited trial regarding venBio's actions
Friday, 3 Mar 2017 10:19am EST 

Immunomedics Inc : Continue to pursue legally justified relief against venBio Select Advisor LLC and venBio's four director candidates in court . Immunomedics intends to proceed with its annual meeting scheduled for Friday . Intends to seek expedited discovery, expedited trial with respect to "questionable actions" actions employed by venBio .Says will promptly seek appropriate relief in a proceeding in Delaware chancery court.  Full Article

Immunomedics enters licensing agreement with Seattle Genetics
Friday, 10 Feb 2017 06:50am EST 

Immunomedics Inc - : Immunomedics enters into exclusive global licensing agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with potential payments of up to approximately $2 billion, plus royalties . For limited period, through Feb 19, 2017, co has right to continue negotiating with select number of parties, and accept superior proposal . Co has right to accept superior proposal, terminate proposed development, license agreement upon payment of termination fee to Seattle Genetics . Immunomedics and Seattle Genetics will each appoint representatives to serve on a joint steering committee . Immunomedics will retain right to elect to co-promote IMMU-132 in United States by participating in 50 pct of sales effort . JSC will be responsible for determining overall development, commercialization, & intellectual property strategy for IMMU-132 . Expects deal to "fulfill" its liquidity needs such that company can fund itself without additional equity raises for foreseeable future . Upon closing of transaction, Immunomedics board and management will evaluate and prioritize company's remaining clinical programs .Seattle genetics to make up to $57 million equity investment for up to 9.9 pct stake in co via immediate purchase of common stock, 3-year warrant.  Full Article

Seattle Genetics Q4 loss per share $0.39
Thursday, 9 Feb 2017 04:02pm EST 

Seattle Genetics Inc : Seattle Genetics reports fourth quarter and year 2016 financial results . Q4 loss per share $0.39 . Sees FY 2017 revenue $405 million to $445 million . Q4 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S . Q4 revenue $105.3 million versus I/B/E/S view $105 million .FY2017 revenue view $494.0 million -- Thomson Reuters I/B/E/S.  Full Article

Seattle Genetics-randomized phase 3 clinical trial with ADCETRIS meets primary endpoint
Monday, 1 Aug 2016 06:59am EDT 

Seattle Genetics Inc : Takeda and Seattle Genetics announce positive data from phase 3 Alcanza clinical trial of ADCETRIS® (Brentuximab Vedotin) for CD30-expressing cutaneous T-Cell Lymphoma . Randomized phase 3 clinical trial with ADCETRIS met primary endpoint . Intend to submit a supplemental biologics license application to FDA in first half of 2017 for approval .Phase 3 trial with ADCETRIS demonstrated highly statistically significant improvement in rate of objective response lasting at least 4 months.  Full Article

Seattle Genetics reports Q2 financial results
Tuesday, 26 Jul 2016 04:02pm EDT 

Seattle Genetics Inc : Sees intiating phase 2 trial of denintuzumab mafodotin (SGN-CD19a; 19A) in frontline diffuse large B-cell lymphoma during 2016. . Seattle Genetics reports second quarter 2016 financial results . Q2 loss per share $0.23 . Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S .Q2 revenue $95.4 million versus I/B/E/S view $94.1 million.  Full Article

More From Around the Web

BRIEF-Seattle Genetics Q1 loss per share $0.42

* Seattle genetics reports first quarter 2017 financial results